CGON Key Statistics, Chart & Performance
The current stock price of CGON is 39.75 USD. In the past month the price decreased by -3.07%. In the past year, price increased by 38.65%.
CGON Latest News, Press Relases and Analysis
CGON Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.07 | 401.99B | ||
| AMGN | AMGEN INC | 14.87 | 175.17B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.25 | 115.62B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 79.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767.65 | 51.72B | ||
| INSM | INSMED INC | N/A | 42.00B | ||
| NTRA | NATERA INC | N/A | 31.52B | ||
| BIIB | BIOGEN INC | 10.5 | 25.78B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.96 | 21.54B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B | ||
| INCY | INCYTE CORP | 15.36 | 19.37B |
Related stock screener links
About CGON
Company Profile
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 113 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Company Info
CG ONCOLOGY INC
400 Spectrum Center Drive, Suite 2040
Irvine CALIFORNIA US
Employees: 113
Phone: 19492886298
CG ONCOLOGY INC / CGON FAQ
Can you describe the business of CG ONCOLOGY INC?
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 113 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
What is the stock price of CG ONCOLOGY INC today?
The current stock price of CGON is 39.75 USD. The price decreased by -2.91% in the last trading session.
Does CGON stock pay dividends?
CGON does not pay a dividend.
What is the ChartMill technical and fundamental rating of CGON stock?
CGON has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of CGON stock?
CG ONCOLOGY INC (CGON) operates in the Health Care sector and the Biotechnology industry.
How many employees does CG ONCOLOGY INC have?
CG ONCOLOGY INC (CGON) currently has 113 employees.
Can you provide the ownership details for CGON stock?
You can find the ownership structure of CG ONCOLOGY INC (CGON) on the Ownership tab.
CGON Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CGON. When comparing the yearly performance of all stocks, CGON is one of the better performing stocks in the market, outperforming 85.73% of all stocks.
CGON Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CGON. While CGON seems to be doing ok healthwise, there are quite some concerns on its profitability.
CGON Financial Highlights
Over the last trailing twelve months CGON reported a non-GAAP Earnings per Share(EPS) of -2.04. The EPS increased by 61.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.75% | ||
| ROE | -22.03% | ||
| Debt/Equity | 0 |
CGON Forecast & Estimates
20 analysts have analysed CGON and the average price target is 73.1 USD. This implies a price increase of 83.9% is expected in the next year compared to the current price of 39.75.
For the next year, analysts expect an EPS growth of -55.21% and a revenue growth 82.98% for CGON